Baricitinib for the Lung Injury Following Spontaneous SAH
NCT06439615
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Spontaneous Subarachnoid Hemorrhage
Interventions
DRUG:
Baricitinib 4 MG
OTHER:
Standard treatment
Sponsor
Tang-Du Hospital